In the wake of a disaster, Cempra shares shoot up on a promising PhIII antibiotic matchup
Just two months after taking a beating on the FDA’s decisive rejection of Cempra’s antibiotic solithromycin, the biotech has been redeemed by the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
